Press Releases
Focusing on Markets with Unmet Needs
Insmed is a research-driven biopharmaceutical company with broad expertise in and innovative approaches to the development of protein-based therapeutics, and efficiently moving product candidates through the regulatory approval process.
Follow-On Biologics
On February 12, 2009 we announced that we had entered into a definitive agreement with Merck & Co., Inc. whereby Merck, through an affiliate, would purchase all assets related to our follow-on biologics platform. On March 31, 2009, we completed the sale of these assets for an aggregate purchase price of $130 million. After fees, taxes and other costs related to the transaction, we expect net proceeds of approximately $125 million as a result of this transaction.